The purpose of this study is to determine if candidate polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-o-methyl transferase (COMT) are predictive of psychosis disorder severity, symptomology, and resolution in patients at BCPP. A secondary objective will be to form a biorepository of blood and saliva samples from patients at BCPP so that further genetic, proteonomic and pharmacogenomic studies may be done to gain insight into the genetic basis of differences in psychosis disorder presentation and manifestation, and differences in response to antipsychotic drug treatment.
This is a population-based, genetic-association, candidate polymorphism study. It will involve a prospective and a retrospective component. A blood draw or saliva sample will be performed during the participant's admission to BCPP, which may occur at any point during the participant's length of stay. When a participant has been deemed 'Ready for Discharge' by his/her attending psychiatrist at BCPP, a full phenotype will be obtained via retrospective chart review. Genetic analyses and determination of protein levels will be performed after chart review. Following fulfillment of the primary study objective, the remaining blood and saliva samples will be stored in the biobank over the long-term.
Study Type
OBSERVATIONAL
Enrollment
200
Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
University of British Columbia Hospital - BC Psychosis Program
Vancouver, British Columbia, Canada
RECRUITINGCreation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies.
A biobank of stored samples will be used to determine the genetic variability in psychosis disorder.
Time frame: One visit during participant's stay at BCPP, an expected average of 6 months
Identification of single-nucleotide polymorphisms (SNPs) in the BDNF and COMT genes
We will determine if specific genetic variants in BDNF and COMT genes are associated with psychosis disorder severity, symptomology and resolution.
Time frame: One visit during participant's stay at BCPP, an expected average of 6 months
Medical Chart Review
A medical chart review will be done on hard-copy medical charts at BCPP.
Time frame: One visit during participant's stay at BCPP, an expected average of 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.